Spero Therapeutics Inc expected to post earnings of 4  cents a share - Earnings Preview

Spero Therapeutics

28/03/2023 22:12

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 30. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 733.3% increase in revenue to $22.867 million from $2.74
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Spero Therapeutics
Inc is
for earnings of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6​, above​ its last closing price of $1.41.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.31       -0.30      -0.33     Missed  -8.8
 Jun. 30 2022  -0.92       -0.93      -0.87     Beat    6.1
 Mar. 31 2022  -0.86       -0.87      -1.01     Missed  -16.2​
 Dec. 31 2021  -0.78       -0.75      -0.90     Missed  -20.4
 ​​Sep.        -0.64       -0.66      -0.70     Missed  -5.5
 30 2021                                                
 Jun. 30 2021  -0.74       -0.75      -0.63     Beat    16.1​
 Mar. 31 2021  -0.64       -0.64      -0.66     Missed  -2.3
 Dec. 31 2020  -0.65       -0.74      -0.68     Beat    8.5
 This summary was machine generated March 28 at 21:12 GMT.  All
figures in US dollars  unless otherwise stated